Mar 06,2018

WellDoc's refined consumer diabetes management service comes to Samsung phones

Samsung Health users will now have access to a new consumer-grade version of WellDoc’s digital diabetes management platform, the two companies announced this morning.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 14,2018

Six-month Glooko pilot shows increased engagement, glucose control among T2 diabetes patients

A six-month pilot program conducted by Sharp Rees-Stealy Medical Group in San Diego found that diabetes patients using Glooko’s care management platform were more engaged with their care and achieved better control of their blood glucose levels, according to a case study released by the company.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 16,2018

J&J gets $2.1B offer to sell Lifescan glucometer business

Platinum Equity, a Los Angeles-based global investment firm focused on mergers, acquisitions, and operations, has made a binding offer to acquire Johnson & Johnsons' Chesterbrook, Pennsylvania and Zug, Switzerland-based LifeScan business, which sells the OneTouch line of connected and non-connected glucometers. Platinum Equity will pay $2.1 billion for the business, which reported $1.5 billion in net revenue last year. Assuming the offer is accepted, the transaction is expected to close by the end of the year.

#bgm

View Analyst & Ambassador Comments
Go to original news
Mar 19,2018

Video diabetes consultations offer HbA1c declines, quicker care to veterans

Veterans with Type 2 diabetes who received remote consultations via telehealth achieved glycemic control that was similar to, but not quite on par with, those attending face-to-face visits. On the flip side, these patients were able to complete their diabetes consultations an average 27 days earlier, offering a potential model for those unable to conveniently receive in-person specialty care, according to data recently presented at the Endocrine Society’s annual meeting in Chicago.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Mar 20,2018

Study finds wearable heart rate monitors feasible for early detection of hypoglycemia

Data from a team of Dutch researchers presented this weekend at the Endocrinology Society’s annual meeting in Chicago demonstrated how vital monitoring wearables could identify Type 1 diabetes patients’ hypoglycemic events by measuring heart rate.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 20,2018

Medtronic MiniMed improves glycemic outcomes for kids with T1 diabetes

In-home hybrid closed-loop system MiniMed from Medtronic can help kids with Type 1 diabetes improve their glycemic outcomes, according to a recent abstract that was presented at the meeting of Endocrine Society in Chicago on Saturday. The study, which was funded by Metronic, set out to look at the impact of the system on children aged seven to 13 years. Currently the MiniMed is only FDA approved for individuals over the age of 14. Wood and colleagues compared data from the children with 30 adolescences aged 14 to 21 years and 75 adults over the age of 22.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 27,2018

DarioHealth granted 510(k) clearance for Apple Lightning-compatible glucose monitor

Israel-based DarioHealth has been granted 510(k) clearance for a version of its Blood Glucose Monitoring System that, alongside the Dario app, is compatible with iPhone 7, 8, and X, according to a statement from the company.

REGULATORY FDA

#bgm

View Analyst & Ambassador Comments
Go to original news
Mar 28,2018

Bigfoot Biomedical closes Series B financing round with $55M

A diabetes startup that uses artificial intelligence, Bigfoot Biomedical, has just announced that it scored a total of $55 million in Series B equity financing with new investments from Abbott and other existing funders.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Mar 01,2018

Roche signs collaboration agreement to expand access to therapy information by integrating insulin data from connected pens to its open ecosystem

Roche announced today that it has signed a development and collaboration agreement with Novo Nordisk, a global leader in innovating the therapy of diabetes and obesity. Under the terms of this agreement, Roche and Novo Nordisk will work together to integrate insulin dosage information from Novo Nordisk’s connected pen technology into Roche’s open ecosystem, communicating with its digital diabetes management solutions including mySugr. People with diabetes spend an average of one hour per day on self-carei and have to make up to 50 therapy decisions daily. Digital health solutions have the potential to ease this constant burden and as such to support better therapy adherence and improved outcomes.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 01,2018

Tandem Diabetes Care Announces 2017 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the year and quarter ended December 31, 2017 and financial guidance for the year ending December 31, 2018. "The fourth quarter marked the strongest sales in Tandem's history, with 80 percent growth in our sequential quarterly pump shipments. This strong demand for the t:slim X2 Insulin Pump was driven by our successful launch of integration with Dexcom G5 Mobile CGM and our unique offering that allows customers to remotely update their pump software using a personal computer," said Kim Blickenstaff, President and Chief Executive Officer.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES